• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Science & Research

  • Print
  • Share
  • E-mail

FDA Pediatric Safety Communications


Safety Issue and Web Address
June 26, 2014Oral viscous lidocaine  2% solutionAlert informing health care professionals and the public about a new Boxed Warning for the product labeling.  The product should not to be used to treat infants and young children with teething pain. The oral viscous lidocaine solution is not approved for this indication and can cause death, problems with the heart, severe brain injury and seizures.
June 25, 2014Over- the-counter  acne products (such as Proactiv, Neutrogena, MaxClarity, Oxy, Ambi, Aveeno, Clean&Clear, and as store brands)Alert warning health care professionals and the public about the rare but serious and potential life threatening allergic reactions or severe irritation. Consumers should stop using their topical acne product and seek emergency medical attention immediately if they experience hypersensitivity reactions such as throat tightness; difficulty breathing; feeling faint; or swelling of the eyes, face, lips, or tongue.  Consumers should also stop using the product if they develop hives and itching.
Mar. 31, 2014Revatio (sildenafil)Update clarifying the strength of the warning communicated in the revised product label in August 2012 (see below). The warning stated that “use of Revatio, particularly chronic use, is not recommended in children”. This recommendation was not intended to suggest that Revatio should never be used in children. This warning should not be interpreted as a contraindication. Revatio may be used with close monitoring in individual children when other treatment options are limited and benefit outweighs the risk.
Dec. 17, 2013Concerta (methylphenidate hydrochloride), Daytrana (methylphenidate), Focalin and Focalin XR (dexmethylphenidate hydrochloride), Metadate CD and Metadate ER (methylphenidate hydrochloride), Methylin and Methylin ER (methylphenidate hydrochloride), Quillivant XR (methylphenidate hydrochloride), Ritalin, Ritalin LA, and Ritalin SR (methylphenidate hydrochloride)Alert warning health care professionals and the public about the rare but serious risk of priapism (prolonged and sometimes painful erections) with methylphenidate products used to treat attention deficit hyperactivity disorder (ADHD). Notably, the majority of the 15 cases of priapism reported to the FDA between 1997-2012 occurred in males less than 18 years of age. Some patients were hospitalized for treatment, including two who required surgical intervention: one with shunt placement and another with needle aspiration of the corpus cavernosum.
Feb. 26, 2013Sensipar (cinacalcet hydrochloride)Alert informing healthcare professionals that FDA suspended all pediatric clinical trials of Sensipar (cinacalcet hydrochloride) after a recent death of a 14-year-old patient in a trial. FDA continues to gather information on the circumstances surrounding the patient’s death.  
Feb. 20, 2013Codeine and Codeine-Containing ProductsUpdate informing health care professionals and the public about a new Boxed Warning and Contraindication in the drug label of codeine-containing products about the risk of codeine in post-operative pain management in children following tonsillectomy and /or adenoidectomy.
Oct. 25, 2012Over the-counter tetrahydrozoline, oxymetazoline, or naphazoline containing eye drops and nasal decongestant spraysAlert informing health care professionals about serious adverse events from accidental ingestion of over-the-counter redness-relief eye drops or nasal decongestant sprays by children 5 years of age and younger. These products are sold under various brand names, as generics, and as store brands (see List of Products in the safety communication).
Aug. 30, 2012Revatio (silfenadil)Alert informing healthcare professionals not to prescribe sildenafil to children (ages 1 through 17 years) for pulmonary arterial hypertension (PAH) due to higher risk of death with high doses and low doses are ineffective at improving exercise ability.
Aug. 15, 2012 Codeine and Codeine-Containing ProductsAlert informing healthcare professionals and the public about the risk of rare, but life-threatening adverse events or death on the use of codeine in certain children after tonsillectomy and/or adenoidectomy.
Dec. 14, 2011Celexa (citalopram); Lexapro (escitalopram); Prozac, Sarafem, Symbyax (fluoxetine); Luvox, Luvox CR (fluvoxamine); Paxil, Paxil CR, Pexeva (paroxetine); Zoloft (sertraline); Viibryd (vilazodone) Update informing healthcare professionals and the public on the use of selective serotonin reuptake inhibitor (SSRI) antidepressants by women during pregnancy and the potential risk of a rare heart and lung condition known as Persistent Pulmonary Hypertension of the Newborn (PPHN).
Nov. 3, 2011Tumor necrosis factor (TNF) blockers [Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab pegol) and Simponi (golimumab)Update informing healthcare professionals and the public about the ongoing safety of Tumor Necrosis Factor (TNF) blockers and malignancies (cancer) in children, adolescents, and young adults (30 years of age or younger).
Aug. 4, 2011Recombinant Human Growth Hormone (somatropin)Update informing the public about the ongoing safety review of human growth hormone (somatropin) and possible increased risk of death.
July 11, 2011Tamiflu (oseltamivir phosphate) for Oral SuspensionAlert informing healthcare professionals of important product safety changes made to reduce the possibility of prescribing and dosing confusion that can lead to medication errors.
May 20, 2011SimplyThick Alert informing healthcare professionals and the public not to feed SimplyThick to infants born before 37 weeks gestation because of the risk of necrotizing enterocolitis (NEC), a life-threatening condition characterized by inflammation and death of intestinal tissue.
Mar. 8, 2011Kaletra (lopinavir/ritonavir)
New warning to the product labeling of Kaletra (lopinavir/ritonavir) oral solution that use should be avoided in preterm infants in the immediate postnatal period because of the possible toxicity associated with the product.
Dec. 14, 2010Tessalon (benzonatate)
Alert notifying the public that accidental ingestion of benzonatate by children under the age of 10 years can result in death from overdose.
Sep. 15, 2010Valcyte (valganciclovir hydrochloride)Alert informing healthcare professionals about new pediatric dosing recommendations to prevent potential Valcyte (valganciclovir) overdose in pediatric transplant patients.
July 29, 2010Evamist (estradiol transdermal spray)Ongoing safety review of adverse effects including premature puberty from Evamist in children who may have been unintentionally exposed to the drug through skin contact with women using this product. FDA has also received reportes of inadvertent exposure in pets.
June 15, 2010Vitamin D Supplement Products Alert advising that some liquid Vitamin D supplement products sold with droppers could allow parents to accidentally give harmful amounts of Vitamin D to their infant.
June 2, 2010Serevent Diskus (Salmeterol); Foradil Aerolizer (Formoterol); Foradil Certihaler* (Formoterol); Advair Diskus (Salmeterol/Fluticasone); Advair HFA (Salmeterol/Fluticasone); Symbiort (Formoterol/Budesonide); Brovana (Arformoterol); Perforomist (Formoterol)Update highlighting information about appropriate use of long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs).


* Not currently marketed in the U.S.